Company Profile
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Latest News
This Stock Market Is Full of Bargains, Our Roundtable Pros Say. 45 Picks for the Second Half.
Vaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now
Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://vaxcyte.com |
| Audit Risk | 3 |
| Board Risk | 6 |
| Overall Risk | 7 |
| Market Cap | 7.89B |
| Forward P/E | -7.37 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -6.89 |
| Forward EPS | -7.42 |
| Book Value | 20.76 |
| Price-to-Book | 2.63 |
| Enterprise-to-EBITDA | -5.85 |
| Short Ratio | 7.67 |
| Earnings Date | 08/05/2026 |
| Earnings Call Date | |
| Earnings Average | -2.1 |
| Earnings Low | -2.55 |
| Earnings High | -1.47 |
| Revenue Average | 0 |
| Revenue Low | 0 |
| Revenue High | 0 |